| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00018-016-2345-4 |
| P698 | PubMed publication ID | 27563707 |
| P2093 | author name string | Hui Yang | |
| Jing Qu | |||
| Yuan Zheng | |||
| Yan Zheng | |||
| Jianliang Zhang | |||
| Shuqing Yu | |||
| P2860 | cites work | Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers | Q22251089 |
| The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease | Q22306292 | ||
| Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models | Q24315670 | ||
| A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment | Q24618342 | ||
| Prions | Q24633319 | ||
| Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist | Q24799009 | ||
| Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers | Q26765458 | ||
| Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment | Q26799893 | ||
| Nucleic acid aptamers: research tools in disease diagnostics and therapeutics | Q26824321 | ||
| Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism | Q27315907 | ||
| Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein | Q27656952 | ||
| Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase | Q27860794 | ||
| In vitro selection of RNA molecules that bind specific ligands | Q27861109 | ||
| Functional proteins from a random-sequence library | Q28362000 | ||
| Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies | Q28476061 | ||
| Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model | Q28550356 | ||
| Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns | Q29392099 | ||
| Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection | Q29617433 | ||
| Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen | Q30739257 | ||
| Aptamers: an emerging class of molecules that rival antibodies in diagnostics | Q30764345 | ||
| Peptide aptamers: tools for biology and drug discovery | Q30764480 | ||
| RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity | Q30879431 | ||
| Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. | Q31151988 | ||
| Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling | Q31166485 | ||
| Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease | Q33259103 | ||
| Selection of aptamers for molecular recognition and characterization of cancer cells | Q33285855 | ||
| SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands | Q33290703 | ||
| Advances in SELEX and application of aptamers in the central nervous system | Q33293314 | ||
| Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, and targeted therapy | Q33791768 | ||
| DNA aptamer evolved by cell-SELEX for recognition of prostate cancer | Q33793416 | ||
| Automated selection of anti-protein aptamers | Q33954658 | ||
| An RNA motif that binds ATP | Q34058538 | ||
| LNA: a versatile tool for therapeutics and genomics | Q34175818 | ||
| Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method. | Q34303977 | ||
| Comparison of different methods for generation of single-stranded DNA for SELEX processes | Q34317021 | ||
| RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity | Q38360485 | ||
| Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy | Q38383216 | ||
| Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics. | Q38443249 | ||
| Aptamer Oligonucleotides: Novel Potential Therapeutic Agents in Autoimmune Disease | Q38494145 | ||
| A Highlight of Recent Advances in Aptamer Technology and Its Application | Q38541697 | ||
| NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein | Q38562137 | ||
| Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease | Q38722255 | ||
| Enhancing aptamer function and stability via in vitro selection using modified nucleic acids | Q38787655 | ||
| 3D Cell-SELEX: Development of RNA aptamers as molecular probes for PC-3 tumor cell line. | Q38798663 | ||
| PEI protected aptamer molecular probes for contrast-enhanced in vivo cancer imaging | Q39307748 | ||
| Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. | Q39511979 | ||
| Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells | Q39776245 | ||
| Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA. | Q39975907 | ||
| Aptamer:toxin conjugates that specifically target prostate tumor cells | Q40267091 | ||
| Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery | Q40390348 | ||
| Clinical applications of nucleic acid aptamers in cancer | Q42332603 | ||
| Molecular recognition of small-cell lung cancer cells using aptamers | Q42720667 | ||
| Effects of charge density and hydrophobicity of poly(amido amine)s for non-viral gene delivery | Q42957790 | ||
| Screening of DNA aptamer against mouse prion protein by competitive selection | Q43189229 | ||
| Structural determinants of conformationally selective, prion-binding aptamers. | Q44719244 | ||
| Biomedicine. Parkinson's--divergent causes, convergent mechanisms. | Q44904985 | ||
| Extracellular potentials recording in intact taste epithelium by microelectrode array for a taste sensor | Q44941927 | ||
| Pegaptanib for neovascular age-related macular degeneration | Q45206481 | ||
| Uncovering the true prevalence of Huntington's disease | Q45298664 | ||
| Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers | Q46765690 | ||
| Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. | Q46904762 | ||
| Simultaneous tracking of drug molecules and carriers using aptamer-functionalized fluorescent superstable gold nanorod-carbon nanocapsules during thermo-chemotherapy | Q48622833 | ||
| Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging | Q50675322 | ||
| Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. | Q50724125 | ||
| Sodium dodecyl sulfate-modified carbon paste electrodes for selective determination of dopamine in the presence of ascorbic acid. | Q51163851 | ||
| Aptamers as therapeutics. | Q51813594 | ||
| Automated RNA selection. | Q52230208 | ||
| An ultrasensitive nanowire-transistor biosensor for detecting dopamine release from living PC12 cells under hypoxic stimulation. | Q54763443 | ||
| In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection | Q56902246 | ||
| In vitro selection of dopamine RNA ligands | Q73561259 | ||
| Bringing picomolar protein detection into proximity | Q78021697 | ||
| In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis | Q80554058 | ||
| A novel label-free electrochemical aptasensor based on graphene-polyaniline composite film for dopamine determination | Q95805563 | ||
| Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. | Q34326301 | ||
| Epidemiology. Paths from pesticides to Parkinson's | Q34364387 | ||
| Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. | Q34375960 | ||
| Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. | Q34473279 | ||
| Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | Q34499843 | ||
| Dopamine and the diseased brain | Q34513611 | ||
| Recent trends in SELEX technique and its application to food safety monitoring | Q34552324 | ||
| Nanoparticles in medicine: therapeutic applications and developments | Q34655287 | ||
| Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. | Q35012627 | ||
| Aptamers evolved from live cells as effective molecular probes for cancer study | Q35033059 | ||
| Current approaches in SELEX: An update to aptamer selection technology. | Q35566463 | ||
| The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells | Q35567561 | ||
| Progress in selection and biomedical applications of aptamers. | Q35635898 | ||
| Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution | Q35779820 | ||
| Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. | Q35970606 | ||
| Pegaptanib: in exudative age-related macular degeneration | Q36201593 | ||
| Screening of aptamers on microfluidic systems for clinical applications | Q36239152 | ||
| DNA Aptamer Based Nanodrugs: Molecular Engineering for Efficiency | Q36498635 | ||
| Ion-dependent conformational switching by a DNA aptamer that induces remyelination in a mouse model of multiple sclerosis. | Q36559199 | ||
| Bioactive and nuclease-resistant L-DNA ligand of vasopressin | Q36591985 | ||
| Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. | Q36664193 | ||
| Cyclic amplification and selection of targets (CASTing) for the myogenin consensus binding site | Q36728377 | ||
| GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A. | Q36777244 | ||
| Complex target SELEX. | Q37056570 | ||
| Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany | Q37221529 | ||
| Application of locked nucleic acids to improve aptamer in vivo stability and targeting function | Q37619467 | ||
| α-Synuclein: membrane interactions and toxicity in Parkinson's disease | Q37760521 | ||
| Development of aptamer therapeutics | Q37773719 | ||
| Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases | Q37815481 | ||
| Aptamers: selection, modification and application to nervous system diseases | Q37916660 | ||
| Single-stranded DNA (ssDNA) production in DNA aptamer generation | Q37982285 | ||
| Prion propagation, toxicity and degradation | Q38021894 | ||
| The application of aptamers in cancer research: an up-to-date review | Q38087391 | ||
| The remarkable conformational plasticity of alpha-synuclein: blessing or curse? | Q38104514 | ||
| Three-dimensional perfused cell culture | Q38159091 | ||
| Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease? | Q38175706 | ||
| Aptamers: problems, solutions and prospects | Q38181121 | ||
| Aptamers as a replacement for antibodies in enzyme-linked immunosorbent assay | Q38256321 | ||
| Aptamers as promising molecular recognition elements for diagnostics and therapeutics in the central nervous system | Q38258163 | ||
| In vitro Selection of DNA Aptamers to Glioblastoma Multiforme. | Q38274697 | ||
| Bioinformatic analysis of the contribution of primer sequences to aptamer structures | Q38289647 | ||
| Use of magnetic beads in selection and detection of biotoxin aptamers by electrochemiluminescence and enzymatic methods | Q38292683 | ||
| Tenascin-C aptamers are generated using tumor cells and purified protein | Q38296050 | ||
| In vitro selection of RNA ligands to substance P. | Q38296387 | ||
| Myelin Basic Protein and a Multiple Sclerosis-related MBP-peptide Bind to Oligonucleotides. | Q38304326 | ||
| Cell-SELEX-based selection of aptamers that recognize distinct targets on metastatic colorectal cancer cells. | Q38306874 | ||
| Selection of DNA ligands for protein kinase C-delta. | Q38308752 | ||
| RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 in vitro | Q38310913 | ||
| Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras | Q38311731 | ||
| Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood | Q38311833 | ||
| Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo | Q38312416 | ||
| Molecular recognition of amino acids by RNA aptamers: the evolution into an L-tyrosine binder of a dopamine-binding RNA motif. | Q38312753 | ||
| Characterization and application of a novel RNA aptamer against the mouse prion protein | Q38314743 | ||
| DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity | Q38316301 | ||
| RNA aptamer-based electrochemical biosensor for selective and label-free analysis of dopamine | Q38319549 | ||
| Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery | Q38333122 | ||
| Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells | Q38334788 | ||
| In vivo Fluorescence Imaging of Tumors using Molecular Aptamers Generated by Cell‐SELEX | Q38341267 | ||
| Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease. | Q38342641 | ||
| In vitro selection of DNA to chloroaromatics using magnetic microbead-based affinity separation and fluorescence detection | Q38346074 | ||
| Mirror-design of L-oligonucleotide ligands binding to L-arginine | Q38353220 | ||
| P433 | issue | 4 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 683-695 | |
| P577 | publication date | 2016-08-25 | |
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | Aptamer and its applications in neurodegenerative diseases | |
| P478 | volume | 74 |
| Q37679265 | Amyloid-beta immunotherapy: the hope for Alzheimer disease? |
| Q90746310 | Aptamer-guided extracellular vesicle theranostics in oncology |
| Q55007427 | Aptamers Selected for Recognizing Amyloid β-Protein-A Case for Cautious Optimism. |
| Q92776477 | Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model |
| Q48087924 | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics. |
| Q47343593 | Investigation of the interactions between aptamer and misfolded proteins: From monomer and oligomer to fibril by single-molecule force spectroscopy |
| Q88954180 | Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation |
| Q47104247 | Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery. |
| Q38288126 | Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids |
Search more.